Two disparate ligand-binding sites in the human P2Y1 receptor

Nature

Volumn 520, Issue 7547, 2015, Pages 317-321

  Zhang, Dandan ^a   Gao, Zhan Guo ^b   Zhang, Kaihua ^a   Kiselev, Evgeny ^b   Crane, Steven ^b   Wang, Jiang ^a   Paoletta, Silvia ^b   Yi, Cuiying ^a   Ma, Limin ^a   Zhang, Wenru ^a   Han, Gye Won ^c   Liu, Hong ^a   Cherezov, Vadim ^c   Katritch, Vsevolod ^c   Jiang, Hualiang ^a   Stevens, Raymond C ^c,d   Jacobson, Kenneth A ^b   Zhao, Qiang ^a   Wu, Beili ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d SHANGHAITECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 IODO 6 METHYLAMINO 9H PURIN 9 YL) 2 PHOSPHONOOXYBICYCLO[3.1.0]HEXANE 1 METHANOL; ANTICOAGULANT AGENT; G PROTEIN COUPLED RECEPTOR; PURINERGIC P2Y1 RECEPTOR; 1-BENZYLOXYMETHYL-5-ETHYL-6-(ALPHA-PYRIDYLTHIO)URACIL; 2-IODO-N(6)-METHYL-(N)-METHANOCARBA-2'-DEOXYADENOSINE-3',5'-BISPHOSPHATE; ADENOSINE DIPHOSPHATE; DEOXYADENOSINE PHOSPHATE; LIGAND; METHYLTHIO-ADP; NUCLEOTIDE; PURINERGIC P2Y RECEPTOR ANTAGONIST; URACIL;

CHEMICAL BINDING; DRUG; LIGAND; PROTEIN;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG MECHANISM; HUMAN; LIGAND BINDING; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN STRUCTURE; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; METABOLISM; X RAY CRYSTALLOGRAPHY;

ADENOSINE DIPHOSPHATE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DEOXYADENINE NUCLEOTIDES; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y1; THIONUCLEOTIDES; URACIL;

EID: 84928469118     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14287     Document Type: Article

References (37)

1. Abbracchio, M. P. et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58, 281-341 (2006).
2. Gachet, C. P2 receptors, platelet function and pharmacological implications. Thromb. Haemost. 99, 466-472 (2008).
3. Jacobson, K. A., Deflorian, F., Mishra, S. & Costanzi, S. Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal. 7, 305-324 (2011).
4. Jin, J. & Kunapuli, S. P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl Acad. Sci. USA 95, 8070-8074 (1998).
5. 1 receptor in purinergic regulation of TNFalpha-induced vascular inflammation. Circulation 123, 2404-2413 (2011).
6. 2+ wave propagation in dorsal spinal cord astrocytes. J. Neurosci. 20, 2800-2808 (2000).
7. Neary, J. T., Kang, Y., Willoughby, K. A. & Ellis, E. F. Activation of extracellular signal-regulated kinase by stretch-induced injury in astrocytes involves extracellular ATP and P2 purinergic receptors. J. Neurosci. 23, 2348-2356 (2003).
8. 1 receptor antagonists. J. Med. Chem. 46, 4974-4987 (2003).
9. 1 receptor with strong antithrombotic activity in mice. J. Pharmacol. Exp. Ther. 316, 556-563 (2006).
10. 1 antagonists. J. Med. Chem. 56, 1704-1714 (2013).
11. Zhang, C. et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387-392 (2012).
12. White, J. F. et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513 (2012).
13. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
14. Tan, Q. et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-1390 (2013).
15. Wu, H. et al. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485, 327-332 (2012).
16. Ballesteros, J. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366-428 (1995).
17. 12 receptor. Nature 509, 119-122 (2014).
18. 12 receptor in complex with an antithrombotic drug. Nature 509, 115-118 (2014).
19. Costanzi, S., Mamedova, L., Gao, Z. G. & Jacobson, K. A. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J. Med. Chem. 47, 5393-5404 (2004).
20. 1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J. Med. Chem. 41, 1456-1466 (1998).
21. 1 receptor. Drug Dev. Res. 57, 173-181 (2002).
22. 1 antagonist. J. Med. Chem. 56, 9275-9295 (2013).
23. 1 antagonists as novel antiplatelet agents. J. Med. Chem. 57, 6150-6164 (2014).
24. 1 antagonists with improved aqueous solubility. Bioorg. Med. Chem. Lett. 23, 3239-3243 (2013).
25. Hildebrand, P. W. et al. A ligand channel through the G protein coupled receptor opsin. PLoS ONE 4, e4382 (2009).
26. Hanson, M. A. et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851-855 (2012).
27. Srivastava, A. et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124-127 (2014).
28. Park, J. H., Scheerer, P., Hofmann, K. P., Choe, H. W. & Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183-187 (2008).
29. Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469, 175-180 (2011).
30. 2A adenosine receptor. Science 332, 322-327 (2011).
31. Chun, E. et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967-976 (2012).
32. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009).
33. Kabsch, W. Xds. Acta Crystallogr. D 66, 125-132 (2010).
34. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
35. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihoodmethod. Acta Crystallogr. D 53, 240-255 (1997).
36. Smart, O. S. et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D 68, 368-380 (2012).
37. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).